We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Incyte Stops Phase 3 Study of Jakafi for Pancreatic Cancer
Incyte Stops Phase 3 Study of Jakafi for Pancreatic Cancer
Incyte has discontinued a Phase 3 trial of Jakafi with capecitabine as a second-line treatment for patients with metastatic pancreatic cancer after the combination failed to show sufficient efficacy.